Back

Last step on the ladder: proprotein convertase subtilisin/kexin type 9 (PCSK9).

29 August 2017 (13:10 - 13:25)
Organised by:
Congress Presentation Part of: Are we prepared to reduce LDL-cholesterol at any cost? Drug therapy Open Access ESC Congress 2017

About the speaker

Photo
Professor Lale Tokgozoglu

Hacettepe University, Ankara (Turkiye)

4 More presentations in this session

Presentation thumbnail
Challenges for reaching LDL-C goals in high and very high risk patients.
Professor L. Tokgozoglu (Ankara, TR)
Presentation thumbnail
High potency statins and beyond: benefits of combination therapy.
Doctor M. Farnier (Dijon, FR)
Presentation thumbnail
Cost implications of misunderstanding statin intolerance.
Professor E. Stroes (Amsterdam, NL)
Presentation thumbnail
Conclusion - Are we prepared to reduce LDL-cholesterol at any cost?
Professor L. Tokgozoglu (Ankara, TR)

Access the full session

Session thumbnail
Are we prepared to reduce LDL-cholesterol at any cost?

The Event

Event poster

ESC Congress 2017

29 August 2017 13:10 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of proprotein covertase subtilisin/kexin type 9 inhibitors among patients with acute coronary syndrome: a meta-analysis of randomized controlled trials
27 August 2022
thumbnail
Congress Presentation
Epigenetic regulation of PCSK9 expression by statins
26 August 2023
thumbnail
Congress Presentation
Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study
27 August 2021
thumbnail
Congress Presentation
Association of circulating proprotein convertase subtilisin/kexin type 9 concentration with prothrombin time in patients with chest pain
28 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources